메뉴 건너뛰기




Volumn 23, Issue 10, 2012, Pages 2663-2670

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers

(19)  Seront, E a,b   Rottey, S c   Sautois, B d   Kerger, J e   D'hondt, L A e   Verschaeve, V f   Canon, J L f   Dopchie, C g   Vandenbulcke, J M g   Whenham, N h   Goeminne, J C i   Clausse, M j   Verhoeven, D g   Glorieux, P k   Branders, S b   Dupont, P b   Schoonjans, J l   Feron, O b   Machiels, J P a  


Author keywords

Angiogenesis; Angiopoietin 1; Everolimus; Mammalian target of rapamycin; Transitional carcinoma cell

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOSTATIN; CXCL16 CHEMOKINE; ENDOGLIN; ENDOSTATIN; EVEROLIMUS; GELATINASE B; INSULIN GROWTH FACTOR BINDING PROTEIN 1; INSULIN GROWTH FACTOR BINDING PROTEIN 2; INSULIN GROWTH FACTOR BINDING PROTEIN 3; PENTRAXIN 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATINUM DERIVATIVE; PROLACTIN; SERINE PROTEINASE INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

EID: 84864369495     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds057     Document Type: Article
Times cited : (116)

References (48)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American Cancer Society. Atlanta, GA: American Cancer Society
    • American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society 2011.
    • (2011) Cancer Facts & Figures, 2011
  • 2
    • 0032887956 scopus 로고    scopus 로고
    • Long term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy
    • Bajorin DF, Dodd PM, Mazundar M et al. Long term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181.
    • (1999) J Clin Oncol , vol.17 , pp. 3173-3181
    • Bajorin, D.F.1    Dodd, P.M.2    Mazundar, M.3
  • 3
    • 0030794516 scopus 로고    scopus 로고
    • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
    • Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
    • (1997) J Clin Oncol , vol.15 , pp. 2564-2569
    • Saxman, S.B.1    Propert, K.J.2    Einhorn, L.H.3
  • 4
    • 23044501890 scopus 로고    scopus 로고
    • Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    • von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
    • (2005) J Clin Oncol , vol.23 , pp. 4602-4608
    • von der Maase, H.1    Sengelov, L.2    Roberts, J.T.3
  • 5
    • 75149128685 scopus 로고    scopus 로고
    • Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract
    • Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
    • (2009) J Clin Oncol , vol.27 , pp. 4454-4461
    • Bellmunt, J.1    Theodore, C.2    Demkov, T.3
  • 6
    • 49849098119 scopus 로고    scopus 로고
    • Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
    • Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7: 1347-1354.
    • (2008) Mol Cancer Ther , vol.7 , pp. 1347-1354
    • Garcia, J.A.1    Danielpour, D.2
  • 7
    • 73949109246 scopus 로고    scopus 로고
    • Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk
    • Chen M, Cassidy A, Gu J et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 2009; 30: 2047-2052.
    • (2009) Carcinogenesis , vol.30 , pp. 2047-2052
    • Chen, M.1    Cassidy, A.2    Gu, J.3
  • 8
    • 0032897458 scopus 로고    scopus 로고
    • Somatic mutation of PTEN in bladder carcinoma
    • Aveyard JS, Skilleter A, Habuchi T et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904-908.
    • (1999) Br J Cancer , vol.80 , pp. 904-908
    • Aveyard, J.S.1    Skilleter, A.2    Habuchi, T.3
  • 9
    • 34250687198 scopus 로고    scopus 로고
    • Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
    • Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 7564-7569
    • Saal, L.H.1    Johansson, P.2    Holm, K.3
  • 10
    • 76649128715 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    • Knowles MA, Platt FM, Ross RL et al. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28: 305-316.
    • (2009) Cancer Metastasis Rev , vol.28 , pp. 305-316
    • Knowles, M.A.1    Platt, F.M.2    Ross, R.L.3
  • 11
    • 70349667473 scopus 로고    scopus 로고
    • Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer
    • Platt FM, Hurst CD, Tayler CF et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15: 6008-6017.
    • (2009) Clin Cancer Res , vol.15 , pp. 6008-6017
    • Platt, F.M.1    Hurst, C.D.2    Tayler, C.F.3
  • 12
    • 70350525235 scopus 로고    scopus 로고
    • Activation of the PI3K/Akt pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models
    • Qian CN, Furge KA, Knol J et al. Activation of the PI3K/Akt pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res 2009; 69: 8256-8264.
    • (2009) Cancer Res , vol.69 , pp. 8256-8264
    • Qian, C.N.1    Furge, K.A.2    Knol, J.3
  • 13
    • 0038118495 scopus 로고    scopus 로고
    • VEGF receptor expression and signalling in human bladder tumors
    • Wu W, Shu X, Hovsepyan H et al. VEGF receptor expression and signalling in human bladder tumors. Oncogene 2003; 22: 3361-3370.
    • (2003) Oncogene , vol.22 , pp. 3361-3370
    • Wu, W.1    Shu, X.2    Hovsepyan, H.3
  • 14
    • 2142760062 scopus 로고    scopus 로고
    • The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression
    • Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004; 22: 1-6.
    • (2004) Urol Oncol , vol.22 , pp. 1-6
    • Yang, C.C.1    Chu, K.C.2    Yeh, W.M.3
  • 15
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 16
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
    • (2011) N Engl J Med , vol.364 , pp. 514-523
    • Yao, J.C.1    Shah, M.H.2    Ito, T.3
  • 17
    • 78049510428 scopus 로고    scopus 로고
    • Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
    • Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
    • (2010) N Engl J Med , vol.363 , pp. 1801-1811
    • Krueger, D.A.1    Care, M.M.2    Holland, K.3
  • 18
    • 60549102667 scopus 로고    scopus 로고
    • Rapamycin inhibits in vitro growth release of angiogenetic factors in human bladder cancer
    • Fechner G, Classen K, Schmidt D et al. Rapamycin inhibits in vitro growth release of angiogenetic factors in human bladder cancer. Urology 2009; 73: 665-668.
    • (2009) Urology , vol.73 , pp. 665-668
    • Fechner, G.1    Classen, K.2    Schmidt, D.3
  • 19
    • 75749105837 scopus 로고    scopus 로고
    • Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer
    • Mansure JJ, Nassim R, Chevalier S et al. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8: 2339-2347.
    • (2009) Cancer Biol Ther , vol.8 , pp. 2339-2347
    • Mansure, J.J.1    Nassim, R.2    Chevalier, S.3
  • 20
    • 79955505851 scopus 로고    scopus 로고
    • Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells
    • Chiong E, Lee IL, Dadbin A et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011; 17: 2863-2873.
    • (2011) Clin Cancer Res , vol.17 , pp. 2863-2873
    • Chiong, E.1    Lee, I.L.2    Dadbin, A.3
  • 21
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 22
    • 77951626194 scopus 로고    scopus 로고
    • Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
    • Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-1855.
    • (2010) J Clin Oncol , vol.28 , pp. 1850-1855
    • Bellmunt, J.1    Choueiri, T.K.2    Fougeray, R.3
  • 23
    • 43249131172 scopus 로고    scopus 로고
    • Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum based chemotherapy
    • Beer TM, Goldman B, Nichols CR et al. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum based chemotherapy. Clin Genitourin Cancer 2008; 6: 36-39.
    • (2008) Clin Genitourin Cancer , vol.6 , pp. 36-39
    • Beer, T.M.1    Goldman, B.2    Nichols, C.R.3
  • 24
    • 19344372529 scopus 로고    scopus 로고
    • A phase II study of oxaliplatin in urothelial cancer
    • Winquist E, Vokes E, Moore MJ et al. A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 2005; 23: 150-154.
    • (2005) Urol Oncol , vol.23 , pp. 150-154
    • Winquist, E.1    Vokes, E.2    Moore, M.J.3
  • 25
    • 0031731552 scopus 로고    scopus 로고
    • Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial
    • Witte RS, Manola J, Burch PA et al. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998; 16: 191-195.
    • (1998) Invest New Drugs , vol.16 , pp. 191-195
    • Witte, R.S.1    Manola, J.2    Burch, P.A.3
  • 26
    • 0032127772 scopus 로고    scopus 로고
    • A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer
    • Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-1212.
    • (1998) Eur J Cancer , vol.34 , pp. 1208-1212
    • Lorusso, V.1    Pollera, C.F.2    Antimi, M.3
  • 27
    • 0037083580 scopus 로고    scopus 로고
    • Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
    • Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-940.
    • (2002) J Clin Oncol , vol.20 , pp. 937-940
    • Vaughn, D.J.1    Broome, C.M.2    Hussain, M.3
  • 28
    • 0031005761 scopus 로고    scopus 로고
    • Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
    • McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853-1857.
    • (1997) J Clin Oncol , vol.15 , pp. 1853-1857
    • McCaffrey, J.A.1    Hilton, S.2    Mazumdar, M.3
  • 29
    • 34547865354 scopus 로고    scopus 로고
    • Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group
    • Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007; 110: 759-763.
    • (2007) Cancer , vol.110 , pp. 759-763
    • Dreicer, R.1    Li, S.2    Manola, J.3
  • 30
    • 33746851717 scopus 로고    scopus 로고
    • Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
    • Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24: 3451-3457.
    • (2006) J Clin Oncol , vol.24 , pp. 3451-3457
    • Sweeney, C.J.1    Roth, B.J.2    Kabbinavar, F.F.3
  • 31
    • 67649579849 scopus 로고    scopus 로고
    • A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    • Wulfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-2890.
    • (2009) Cancer , vol.115 , pp. 2881-2890
    • Wulfing, C.1    Machiels, J.P.2    Richel, D.J.3
  • 32
    • 70349501968 scopus 로고    scopus 로고
    • Phase II study of aflibercept (VEGFTrap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial
    • (Abstr e16030)
    • Twardowski P, Stadler W, Frankel P et al. Phase II study of aflibercept (VEGFTrap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial. J Clin Oncol 2009; 27: 15s. (Abstr e16030).
    • (2009) J Clin Oncol , vol.27
    • Twardowski, P.1    Stadler, W.2    Frankel, P.3
  • 33
    • 70149124507 scopus 로고    scopus 로고
    • Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    • Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-4095.
    • (2009) Cancer , vol.115 , pp. 4090-4095
    • Dreicer, R.1    Li, H.2    Stein, M.3
  • 34
    • 77950474660 scopus 로고    scopus 로고
    • Phase II study of sunitinib in patients with metastatic urothelial cancer
    • Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28: 1373-1379.
    • (2010) J Clin Oncol , vol.28 , pp. 1373-1379
    • Gallagher, D.J.1    Milowsky, M.I.2    Gerst, S.R.3
  • 36
    • 84860247115 scopus 로고    scopus 로고
    • Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    • (Abstr 4606)
    • Milowsky MI, Regazzi AM, Garcia-Grossman IR et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011; 29: 15s. (Abstr 4606).
    • (2011) J Clin Oncol , vol.29
    • Milowsky, M.I.1    Regazzi, A.M.2    Garcia-Grossman, I.R.3
  • 37
    • 84860247115 scopus 로고    scopus 로고
    • Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    • (Abstr 245)
    • Milowsky MI, Regazzi AM, Garcia-Grossman IR et al. Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011; 29: 7s. (Abstr 245).
    • (2011) J Clin Oncol , vol.29
    • Milowsky, M.I.1    Regazzi, A.M.2    Garcia-Grossman, I.R.3
  • 38
    • 57349153991 scopus 로고    scopus 로고
    • Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis
    • Satoh N, Yamada Y, Kinugasa Y et al. Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis. Cancer Sci 2008; 99: 2373-2379.
    • (2008) Cancer Sci , vol.99 , pp. 2373-2379
    • Satoh, N.1    Yamada, Y.2    Kinugasa, Y.3
  • 39
    • 14644429809 scopus 로고    scopus 로고
    • Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer
    • Oka N, Yamamoto Y, Takahashi M et al. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 2005; 95: 660-663.
    • (2005) BJU Int , vol.95 , pp. 660-663
    • Oka, N.1    Yamamoto, Y.2    Takahashi, M.3
  • 40
    • 77950633340 scopus 로고    scopus 로고
    • The angiogenic factor angiopoietin-1 is a proneurogenic peptide on subventricular zone stem/progenitor cells
    • Rosa AI, Gonçalves J, Cortes L et al. The angiogenic factor angiopoietin-1 is a proneurogenic peptide on subventricular zone stem/progenitor cells. J Neurosci 2010; 30: 4573-4584.
    • (2010) J Neurosci , vol.30 , pp. 4573-4584
    • Rosa, A.I.1    Gonçalves, J.2    Cortes, L.3
  • 41
    • 0034907326 scopus 로고    scopus 로고
    • Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin
    • Takahashi N, Kawanishi-Tabata R, Haba A et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001; 7: 524-532.
    • (2001) Clin Cancer Res , vol.7 , pp. 524-532
    • Takahashi, N.1    Kawanishi-Tabata, R.2    Haba, A.3
  • 42
    • 17944377486 scopus 로고    scopus 로고
    • Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/Mtor
    • Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 10314-10319
    • Neshat, M.S.1    Mellinghoff, I.K.2    Tran, C.3
  • 43
    • 35348858663 scopus 로고    scopus 로고
    • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    • Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 379-385.
    • (2007) Clin Genitourin Cancer , vol.5 , pp. 379-385
    • Cho, D.1    Signoretti, S.2    Dabora, S.3
  • 44
    • 80052010923 scopus 로고    scopus 로고
    • Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trial group
    • Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trial group. J Clin Oncol 2011; 29: 3278-3285.
    • (2011) J Clin Oncol , vol.29 , pp. 3278-3285
    • Oza, A.M.1    Elit, L.2    Tsao, M.S.3
  • 45
    • 73649109111 scopus 로고    scopus 로고
    • Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163
    • Ellard SL, Clemons M, Gelmon KA et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
    • (2009) J Clin Oncol , vol.27 , pp. 4536-4541
    • Ellard, S.L.1    Clemons, M.2    Gelmon, K.A.3
  • 46
    • 79960732694 scopus 로고    scopus 로고
    • PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
    • Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222-3233.
    • (2011) Oncogene , vol.30 , pp. 3222-3233
    • Weigelt, B.1    Warne, P.H.2    Downward, J.3
  • 47
    • 38849208347 scopus 로고    scopus 로고
    • Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma
    • Cloughesy TF, Yoshimoto K, Ngiemphu P et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
    • (2008) PLoS Med , vol.5
    • Cloughesy, T.F.1    Yoshimoto, K.2    Ngiemphu, P.3
  • 48
    • 33947538050 scopus 로고    scopus 로고
    • Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    • Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
    • (2007) Oncogene , vol.26 , pp. 1932-1940
    • Wan, X.1    Harkavy, B.2    Shen, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.